CD39 inhibition, combined with TIM3 and PD-1 (alone or with CTLA-4 inhibition), improved tumor control, suggesting that scRNA-seq can predict new targets for combinational immunotherapies [28]. This evidence concerns the gene PDCD1 and neoplasm.